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Deposits of complement components have been documented in several human tumors
suggesting a potential involvement of the complement system in tumor immune
surveillance. In vitro and in vivo studies have revealed a double role played by this
system in tumor progression. Complement activation in the cancer microenvironment
has been shown to promote cancer growth through the release of the chemotactic
peptide C5a recruiting myeloid suppressor cells. There is also evidence that tumor
progression can be controlled by complement activated on the surface of cancer
cells through one of the three pathways of complement activation. The aim of this
review is to discuss the protective role of complement in cancer with special focus
on the beneficial effect of complement-fixing antibodies that are efficient activators
of the classical pathway and contribute to inhibit tumor expansion as a result of
MAC-mediated cancer cell killing and complement-mediated inflammatory process.
Cancer cells are heterogeneous in their susceptibility to complement-induced killing
that generally depends on stable and relatively high expression of the antigen and the
ability of therapeutic antibodies to activate complement. A new generation of monoclonal
antibodies are being developed with structural modification leading to hexamer formation
and enhanced complement activation. An important progress in cancer immunotherapy
has been made with the generation of bispecific antibodies targeting tumor antigens
and able to neutralize complement regulators overexpressed on cancer cells. A great
effort is being devoted to implementing combined therapy of traditional approaches
based on surgery, chemotherapy and radiotherapy and complement-fixing therapeutic
antibodies. An effective control of tumor growth by complement is likely to be obtained on
residual cancer cells following conventional therapy to reduce the tumor mass, prevent
recurrences and avoid disabilities.
Keywords: complement systemactivation, tumor control, antibody-based immunotherapy, combination therapies,
antibody
INTRODUCTION
Cancer development is a complex biological process that starts with the malignant transformation
of normal cells caused by genetic alterations and somatic mutations leading to unrestricted cell
proliferation (1). The local microenvironment plays an important role in this process providing
favorable conditions for the seeding of cancer cells in a protective niche that allows the growth
and expansion of the tumor mass (2). Changes in the structural and organizational properties of
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extracellular matrix favor adhesion and migration of cancer
cells from the initial tumor site (3). Active angiogenesis
equally contributes to these environmental changes with the
formation of new leaky vessels that supply growing cancer cells
with nutrients and promote their metastatic spread to distant
organs (4, 5).
Tumor development is constantly controlled by the immune
system that recognizes cancer cells as potential threats to body
homeostasis and mounts a response leading to local recruitment
of effector cells of both innate and adaptive immunity (6).
Although cell-mediated immunity has long been recognized to
play a critical role in tumor eradication through the action of
natural killer cells and cytotoxic T lymphocytes (7, 8), studies
reported in recent years have shown that the complement (C)
system is also an important player in cancer immune surveillance
and these studies have revealed the complex interaction of C
with cancer cells. C components are synthesized by resident
and recruited cells including fibroblasts, endothelial cells, tissue
specific cells, and macrophages (9, 10) and are released in the
tumor microenvironment. Biologically active products generated
as a result of C activation may directly kill cancer cells or
favor their eradication by promoting an inflammatory process.
However, it is important to emphasize that C does not always
provide an effective protection against tumor growth since its
damaging effect on cancer cells can be prevented by C regulatory
proteins (CRPs) over-expressed on the cell surface or by other
mechanisms of cell resistance to C attack. These evasion strategies
are more likely to be operating under conditions of fast tumor
growth.
Recent studies have elucidated a novel aspect of C interaction
with cancer cells showing that it is able to promote rather
than to inhibit tumor development. Markiewski et al. (11)
made the original observation that C5a, released in the
microenvironment as a result of C activation, recruits and
activates myeloid derived suppressor cells that suppress anti-
tumor T-cell responses against HPV-induced cancer. Similar
findings have been reported in other syngeneic models of
mouse tumors invariably associated with C activation (12, 13).
Importantly, C5aR1-deficiency and pharmacological blockade
of C5aR1 by selective C5aR1 antagonists have been shown to
impair tumor growth, pointing to the C5a/C5aR1 signaling
axis as an effector mechanism of C-mediated tumor-promoting
functions (14).
More recently, C1q secreted in the tumor microenvironment
was reported to favor tumor progression by enhancing adhesion,
proliferation, and migration of cancer cells and promoting
angiogenesis independently on C activation (15).
Given these restraints in C-dependent tumor control, the
system has apparently limited chances to provide an effective
defense barrier against cancer development unless the C
protective functions are made more efficient by optimizing the
conditions of its activation and effector activities. In this review,
we shall discuss the strategies that may turn the C system into
a more efficient therapeutic tool by enhancing its activation on
the surface of cancer cells and overwhelming the mechanisms
adopted by tumor cells to evade C attack.
COMPLEMENT ACTIVATION AT TUMOR
SITE
Immunohistochemical analysis of tumor tissue has provided
useful information on the contribution of the C system to
the immune response to cancer revealing the presence of C
components in several solid tumors of different tissues and
organs. Various cell types in tumor tissue including cancer cells
represent the main source of these components which may
also derive, at least in part, from the circulation as a result
of the increased permeability of the tumor vessels. C deposits
have been observed in a number of tumors (16) and in one
study that examined the deposition of various C components in
glioblastoma, C1q was found to be the most highly expressed
component (17). We have recently shown that C1q is present
in various tumors in the absence of other C components and
exerts functions unrelated to C activation (15). However, this
does not exclude C activation at tumor sites as suggested by
tissue deposition of known markers of C activation including
C4d, C3d, and SC5b-9 (18, 19). Local changes in tumor tissue due
to necrosis and apoptosis and, more importantly, inflammation
are responsible for C activation to a degree related to the extent
of these changes, in particular of the inflammatory process.
This suggests that C deposits are likely to be negligible in the
initial stages of tumor growth when the inflammatory reaction is
hardly detectable and is probably more evident at a later stage of
tumor expansion associated with an overt inflammatory reaction.
Tumor cells may partly contribute to C activation using cell-
bound proteases exposed on their surface to cleave C5 and to
generate C5a, which in turn enhances cancer cell invasion (20).
It is not easy to evaluate the impact of C activation at tissue
sites on tumor development because the immunohistochemical
data have mostly been obtained from well-established cancers.
Importantly, C activation products are mainly localized in the
tumor microenvironment and found to be weakly or moderately
bound to some but not all cancer cells, suggesting that they have
limited effect in reducing cell survival. However, it is possible
that C exerts a protective effect in the early phase of cancer
growth, contributing to induce tumor regression, although this
is difficult to ascertain in patients. One way to address this issue
is to utilize mice that develop spontaneous tumors and analyze
the effect of C activation on its progression at tumor sites. Using
BALB/c females expressing the activated rat Her2/neu oncogene,
Bandini et al. (21) have shown that the mammary carcinoma
developing in C3−/− mice manifests faster growth rate and
earlier lung metastasis than the tumor in wild type animals,
suggesting that C activated by antibodies (Abs) directed against
Her2/neu oncogene and/or other tumor-associated antigens may
control tumor growth. Different results were obtained using a
syngeneic mouse model of ovarian cancer which showed similar
growth in wild type and C3−/− mice due to secretion of C3 by
tumor cells that exerts a stimulating effect on cell proliferation
(22). Overall, the available data support a dual role of C in tumor
immune surveillance and its ability to either prevent or promote
tumor progression depends on the characteristics of cancer cells
and the anti-tumor efficiency of the C system.
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TABLE 1 | FDA-approved complement-fixing antibodies.
Target
antigen
INN Company Source Year of first US
FDA (EU EMA)
approval
Therapeutic
indication(s)
CD20 Ibritumomab tiuxetan Biogen Idec Murine IgG1 (type I) 2002 (2004) NHL
Ofatumumab Genmab and GSK Human IgG1 (type I) 2009 (2010) CLL
Rituximab Biogen Idec, Genentech
(Roche)
Chimeric IgG1 (type I) 1997 (1998) NHL; CLL
CD38 Daratumumab Janssen-Cilag, Genmab Human IgG1/κ 2015 (2016) MM
CD52 Alemtuzumab Millennium Pharmaceuticals and
Genzyme
Humanized IgG1 2001 CLL
EGFR Cetuximab ImClone (Eli Lilly),
Merck Serono and BMS
Chimeric IgG1 2004 Head and neck
cancer;
colorectal cancer
GD2 Dinutuximab United Therapeutics
Europe
Human IgG1/κ 2015 Neuroblastoma
HER2 Pertuzumab Roche Humanized IgG1 2012 (2013) Breast cancer
INN, International Non-proprietary Name; NHL, Non Hodgkin Lymphoma; CLL, Chronic Lymphocytic Leukemia; MM, Multiple Myeloma.
CANCER CELLS AS POTENTIAL TARGET
OF COMPLEMENT ATTACK
Expression of tumor-associated molecules on cells undergoing
malignant transformation can lead to C activation on the cell
surface by all three activation pathways. The lectin pathway has
been implicated in C activation on glioma cells which express,
like many other malignant cells, high mannose glycopeptides
that bind MBL and trigger consumption of C4 and C3, but this
reaction fails to induce cell lysis (23). Virus transformed cells
express novel antigens that are able to activate the alternative
pathway, as is the case of EBV-infected B lymphoblastic cell
lines (24–26) and T and monocytic cell lines infected by HIV
(27). The classical pathway of C can be activated on cancer
cells by natural Abs, preferentially of IgM isotype, that recognize
carbohydrate moieties on cell surfaces (28, 29). Cytotoxic Abs
reacting with carbohydrate epitopes of gangliosides GD2 and
GD3 on neuroblastoma and melanoma cell lines have been
detected in a small number of sera from normal individuals (30).
Unfortunately, besides the low frequency, the natural Abs are not
efficient in promoting C-mediated cell killing due to their low
titer and affinity.
Attempts have been made to vaccinate cancer patients with
the aim to induce production of therapeutic Abs. The anti-
tumor response has not always been satisfactory, although a novel
vaccination procedure has recently been developed in rabbits to
stimulate the generation of IgGAbs that cause strong C-mediated
lysis of myeloma cells carrying the CD38 antigen (31).
Despite this improvement, the development of recombinant
Abs against tumor antigens remains the preferential approach
to stimulate selective C activation on cancer cells, although
the identification of specific tumor-associated antigens able to
discriminate cancer cells from healthy tissue still represents
a major limitation in Ab-mediated cancer therapy. A major
progress has been made in the immunotherapy of hematologic
malignancies, in particular those derived from B cells, with the
generation of monoclonal Abs directed against target antigens,
such as CD19 and CD20, present only on B-cells at late
stages of development, and not on hematopoietic stem cells
that are therefore unaffected by the treatment. Conversely, the
development of therapeutic Abs against solid tumors has been
limited by the difficulty to identify specific target antigens on
cancer cells, whether overexpressed self-antigens, or neoantigens
due to tumor-specific mutations or oncogenic viruses.
Only 15 monoclonal Abs have been approved by FDA for the
treatment of all different solid tumors (32), and only 3 of them
are C-fixing molecules, as described in Table 1.
FACTORS AFFECTING THE EFFICIENCY
OF THE ANTIBODIES TO ACTIVATE
COMPLEMENT: THE ANTIBODIES
STRUCTURE
Among the molecular characteristics of recombinant Abs
responsible for C activation, the Ig class is critically important
since human IgM, IgG1, and IgG3 are known to be the
most effective C activators whereas IgG4 fails to bind C1q
(33). The structure of the Fc region of these Abs has been
extensively investigated to improve their therapeutic efficiency
and changes of some amino acids in this region were found to
enhance the Ab activity (34). In particular, computational design
followed by high-throughput screening techniques has allowed
the identification, production, and characterization of Fc variants
with increased ability to bind C1q and to promote C-dependent
cytotoxicity (CDC) (35).
Glycosylation is an important secondary modification of
immunoglobulins that has a significant impact on their
capacity to activate different arms of the immune system.
The addition of conserved glycans, in particular α (1,6)-
linked core fucose, to the Fc region, was shown to be critical
for the interaction of the Ab with the C system (36). This
observation has raised strong research interest in several biotech
companies, resulting in the commercialization of the anti-
CD20 Ab obinutuzumab (Genentech, San Francisco, CA, USA).
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Terminal mannosylation is another important post-translational
modification that prolongs the half-life of the Abs in the
circulation and favors binding of mannose-binding lectin (MBL)
(36). Importantly, the terminal glycosylation of IgG has been
shown to influence CDC without affecting Ab-dependent cell
cytotoxicity (ADCC). In addition, an increased content of
terminal galactose potentiates CDC activity by enhancing the
binding of C1q to the modified Ab (37).
The discovery that hexamerization of Abs after binding to
target antigens leads to a successful activation of the classical
pathway represents a major advance in the development of new
strategies to enhance C activation by IgG (38, 39). The critical
role of this process in C activation is supported by the finding
that some mutations of Fc amino acid sequence of anti-CD20
IgG result in impaired hexamer formation and reduced cell lysis.
Conversely, other mutations have the opposite effect and similar
results were obtained introducing the same mutations in the
IgG4 isotype. A certain degree of flexibility of antigen-bound Abs
allows a conformational change required for hexamerization. The
ability of anti-CD20 Abs to exhibit a more efficient CDC after
hexamer formation is shared also by anti-CD52 and anti-HLA
Abs (38, 39).
FACTORS AFFECTING THE EFFICIENCY
OF THE ANTIBODIES TO ACTIVATE
COMPLEMENT: THE ANTIGEN
Irrespective of the C-activating capacity of anti-tumor Abs, the
characteristics of the target antigen remain of pivotal importance
for a successful tumor cell lysis. The beneficial effects of Abs
in cancer immunotherapy depend on the expression pattern
and the tissue specificity of tumor antigen that should be
present exclusively or predominantly on cancer cells to allow
selective or almost exclusive targeting of tumor cells. It is
equally important that the tumor antigens are expressed also
on metastatic cells which represent the main target of Ab-based
immunotherapy since other therapeutic approaches including
surgery, radiotherapy, and chemotherapy can be used to obtain
an effective control of primary tumor. Moreover, the tumor
antigens should be stably expressed on the cell surface to serve as
useful targets for immunotherapy, whereas intracellular antigens,
though specific for tumor cells, can only be used for diagnostic
purposes. It is important to point out that tumor cells are often
heterogeneous in the expression level of tumor antigens that may
influence their susceptibility to CDC. We have observed that
cells expressing low levels of CD20 isolated by cell sorting from
a population of either chronic lymphocytic leukemia (CLL) or
cancer B-cell lines and kept in culture for over a week give rise
to cells expressing higher level of CD20 that more easily undergo
C-mediated lysis (40, 41). This observation suggests that repeated
injections of Abs administered at appropriate time intervals can
be used to allow the emergence of cell clones expressing higher
levels of CD20 and more susceptible to CDC. Finally, the release
of antigen in the tumor microenvironment and in the circulation
may lead to blockade of therapeutic Ab and contributes to reduce
its expression level on the cell surface, making cancer cells less
susceptible to Ab-mediated C-dependent killing (9).
The number of antigenic sites does not always account for
the capacity of a monoclonal Ab to cause CDC. In this regard,
the impact of the different distribution of two tumor antigens,
the alpha isoform of folate receptor (42) and CD20 (43), on
Ab binding and C activation has been compared. The folate
receptor is associated with epithelial ovarian carcinoma cells and
is expressed on several cell lines at a concentration of about
1 × 106 molecules/cells (44). CD20 is present on cancer B-
cells at a substantially lower expression level of around 40,000–
70,000 molecules/cell (45). Despite the marked difference in the
number of cell-associated antigenic sites, the chimeric anti-CD20
Rituximab is able to activate C (46) and to kill B cells whereas a
chimeric anti-folate receptor Ab fails to do so (42).
Additional factors may play a relevant role in promoting a
more efficient C activation by recombinant Abs, including the
proximity of the target epitopes to the cell surface (47), the
density of target antigen (48), and the Ab-induced movement of
the antigens across the cell membrane (49).
A recent study by Cleary and colleagues provided convincing
evidences that the efficacy of C-mediated killing of cancer cells
induced by Ab is largely influenced by the distance of the
target epitope from the cell membrane and the greater the
distance from the cell surface, the lower the efficiency of cell
lysis (47). They used target cells transfected with fusion proteins
containing either CD20 or CD52 epitopes attached to various
CD137 scaffolds and showed that the cells displaying the target
epitopes closer to the membrane were more susceptible to CDC
than those expressing the epitopes furthest away from the cell
surface. These data clearly suggest that the position of the epitope
in the target antigen is an important factor to consider in the
selection of therapeutic Abs. The surface expression level of
the antigen has been shown to be equally important for an
efficient C activation on both hematological and solid tumors.
Golay et al. (45) analyzed freshly isolated cells from patients
with B-CLL and prolymphocytic leukemia for CDC induced
by Rituximab and found that the C sensitivity of these cells
correlated with the surface expression of CD20. Derer et al. (48)
reached similar conclusions using a fibroblast cell line expressing
different levels of Epithelial Growth Factor Receptor (EGFR)
and reported data indicating that the cell susceptibility to CDC
progressively increased at higher expression level of EGFR. An
increased antigen density resulting from Ab-induced movement
of the tumor-associated antigen across the cell membrane can
also contribute to enhance Ab-dependent C activation. CD20
is an example of a membrane antigen, that is induced by the
type 1 Abs rituximab and ofatumumab to translocate to the lipid
rafts (49). As a consequence, the immune complexes reach a
critical concentration required for hexamer formation and C1q
binding (50).
FACTORS AFFECTING THE EFFICIENCY
OF THE ANTIBODIES TO ACTIVATE
COMPLEMENT: THE COMPLEMENT
SYSTEM
C is an important player in Ab-induced tumor cell death and
has therefore a major impact on the efficacy of therapeutic Abs.
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A clinical observation in patients with CLL treated with Abs
is that the depletion of cancer and normal cells in the blood
of patients is impaired in the presence of reduced levels of C
components (51). Clearance of CLL cells induced by Abs to
CD20 has been shown to be associated with C consumption,
particularly of the early components, which persist for several
days to weeks (52). This would cause a reduced therapeutic
effect of subsequent infusions of the same Abs to control the
malignant cells that circulate in blood in increasing number
due to migration from bone marrow or lymph node. Using an
in vitro model to evaluate the CDC of Burkitt’s lymphoma cell
lines induced by ofatumumab and rituximab, Beurskens et al.
(51) have investigated the effect of different concentrations of
anti-CD20 Abs on cell killing in two consecutive steps. They
found that the dose of anti-CD20 Abs tested in the first step
was critical for the degree of cell killing in the second step.
In particular, using the maximal dose of anti-CD20 Abs in
the first step, the cell lysis did not exceed 30% in the second
step, while the percentage of cell killing increased to over 80%
using a lower Ab concentration in the first step. These data
suggest that the best therapeutic option would be to use the
minimal concentration of Ab to trigger C-mediated killing of
a relatively high number of cells leaving a C level sufficient to
clear newly emerging malignant cells treated with an additional
administration of Ab.
The critical role of C in CDC induced by recombinant
Abs is supported by other uncontrolled studies suggesting that
the killing of cancer B cells could be enhanced based on
supplementation with purified C components or fresh frozen
plasma (53, 54).
The response to immunotherapy of tumors that develop
extravascularly is likely to be different from that of circulating
cells. Unfortunately, it is difficult to evaluate the concentration
of the Ab at cancer site, nor is it easy to measure the activity
of the C system in the tumor microenvironment. However,
the amount of Abs that reaches tumor sites (55) should be
sufficient to activate C if the Abs tend to form hexamers
that require limited amount of C components to activate the
system (39).
Evidence supporting local C deposition was obtained by our
group using a mouse xenograft model of B-cell lymphoma
established in SCID mice with the intraperitoneal injection of
a lymphoma cell line (56). This model is characterized by the
development of peritoneal tumor masses and formation of foci
of lymphoid cells in the spleen, liver, and bone marrow. Injection
of rituximab into tumor-bearing mice resulted in the deposition
of the Ab, C3, and C9 on tumor cells and in prolonged survival of
these animals.
COMPLEMENT-MEDIATED CANCER CELL
DAMAGE AND REGULATION
The importance of late C components in tumor development has
recently been investigated by Verma et al. (57) in a xenogenic
mouse model of B-cell lymphoma. They showed that tumor-
bearing C5 deficient animals treated with rituximab died within
the 52 days period of observation whereas all C5 sufficient
mice survived. Although the tumor tissue was not examined for
complement deposition, the membrane attack complex (MAC)
is likely to have contributed to the C protective effect in this
model.
MAC assembly on the cell membrane is the final step of
C activation. Tumor cell killing caused by Ab-mediated C
activation takes a few minutes to complete under standard
in vitro conditions (52) and is largely mediated by increased
Ca2+ influx and rapid activation of a large variety of enzymes
as a result of MAC insertion (58, 59). C5a and other C
activation products can also contribute to tumor control by
recruiting to the tumor microenvironment inflammatory cells
that cause cell death via C-dependent cell cytotoxicity and
phagocytosis (60).
A large body of evidence has been collected showing that
cancer cells can resist CDC by several different mechanisms
acting either on the cell surface or intracellularly.
Removal of MAC from the cell surface is one of these
mechanisms observed in different tumor cell types after the
activation of the C system by mAbs (61–64). This removal is
usually mediated through membrane vesiculation, directed both
to the inner and the outer sides of cell surface (65).
Overexpression of the membrane-associated C regulatory
proteins (mCRPs) CD46, CD55, and CD59 is anothermechanism
by which cancer cells can evade undesired C attack due to
spontaneous or Ab-induced C activation. The mCRPs act at
different steps of the C sequence by favoring the decay of the C3
convertases (CD55), promoting the degradation of C3b and C4b
(CD46), and preventing the assembly of MAC (CD59) (66, 67).
Because of their high expression level on several tumors, mCRPs
are considered promising targets for cancer immunotherapy.
CD46 has been shown to be highly expressed on colorectal, breast
(68), prostate, lung, liver, and ovarian carcinoma (69) cancer cells.
Elevated levels of CD55 have been documented in a wide range
of cancers including lung, colorectal, gastric, breast, and cervical
cancers as well as in leukemia (66). CD59 is also overexpressed
on different types of carcinoma and sarcoma and on melanoma
cells (70).
An important point to emphasize is that hyper-expression
of mCRPs on the surface of tumor cells does not necessarily
mean that they are equally involved in cell protection from
C attack. Almost two decades ago, we analyzed various B-
lymphoma cell lines for their susceptibility to CDC and
found that all expressed increased levels of CD55, CD46,
and CD59 and were variably resistant to C lysis (46).
However, using neutralizing Abs to mCRPs, we were able
to show that the resistance to C-dependent cell lysis was
abrogated by blocking the inhibitory activity of CD55 and
CD59 whereas inhibition of CD46 was totally ineffective (46).
In contrast, CD46 appears to play a more prominent role
in protecting ovarian cell lines from C attack as suggested
from the substantial increase in C-mediated cell lysis observed
inhibiting CD46 activity with anti-CD46 neutralizing Abs (42).
These findings have important clinical implication for the
selection of mCRP to inhibit in the immunotherapy of different
tumors.
Frontiers in Immunology | www.frontiersin.org 5 September 2018 | Volume 9 | Article 2203
Macor et al. Complement and Tumor Control
THERAPEUTIC STRATEGIES
Antibodies and Complement Activation
Over the past 20 years, therapeutic Abs have rapidly become
the leading product in the biopharmaceutical market. Currently,
there are more than 30 FDA-approved therapeutic Abs for cancer
treatment and some of them are C-fixing Abs that mediate CDC
(Table 1).
Rituximab was the first C-fixing Ab to receive FDA approval
and has been used successfully to treat a large number of patients
with CD20-expressing B-cell malignancies. Because CD20 is
expressed on several B cell-derived cancer cells and also on
normal cells from the late pro-B cell through memory cells,
while absent on plasma cells and precursors hematopoietic stem
cells, it is understandable why treatment with anti-CD20 Abs
induces depletion of cancer cells but does not interfere with the
repopulation of the B-cell compartment (71). Analysis of the
binding mode of anti-CD20 Abs and their epitope specificity has
led to the identification of two types of Abs that differ in their
ability to form distinct complexes with CD20. Type I Abs stabilize
CD20 in lipid rafts leading to stronger C1q binding and increased
C activation whereas type II Abs exhibit reduced C1q binding
that results in lower levels of cell death mediated by CDC (72).
Rituximab, ofatumumab and ibritumomab tiuxetan are
examples of type I Abs known to be efficient activator of the
C cascade (71). On the contrary, type II Abs like tositumumab
performed poorly in CDC (49) and the same was observed for the
optimized type II Ab obinutuzumab which fails to induce CDC
(72, 73). However, Bologna et al. have reported that C plays a role
in cell killing induced by high dose of the type II glycoengineered
anti-CD20 mAb obinutuzumab on B-CLL expressing high levels
of CD20, as suggested by the ability of the anti-C5 Ab eculizumab
to totally prevent cell lysis (74).
In addition to anti-CD20 Abs, other approved C-fixing Abs
directed against various tumor antigens have been recognized
to activate C both in vitro and in vivo including anti-CD52
alemtuzumab (75), anti-CD38 daratumumab (76, 77), anti-EGFR
cetuximab (78, 79), anti-GD2 dinutuximab (80) and anti-HER2
pertuzumab (81).
Strategies to Improve Complement
Activation by Therapeutic Antibodies
Combination of Different Antibodies
The efficiency of C activation on the cell surface is largely
influenced by the epitope density of the antigen recognized by
recombinant Abs which can affect the formation of an adequate
number of immune complexes capable of binding C1q. Two
different strategies have been reported to increase the formation
of C1q-fixing dimers. One approach is to use a combination
of two Abs recognizing different epitopes on the same antigen
sufficiently close to allow juxtaposition of the IgG Abs which
is critical for C1q binding. Spiridon et al. (82) were the first
to analyze C-mediated lysis of Her-2+ human breast cancer
cell lines induced by several mAbs and showed an enhanced
killing using a mixture rather than individual mAbs. Our group
has investigated the C-fixing ability of two Abs, cMOV18, and
cMOV19, that bind to distinct epitopes of the alpha isoform
of folate receptor, highly expressed on epithelial ovarian cancer
cells. Interestingly, the mixture of these two Abs was able to
activate C and to cause death of ovarian cancer cells while
individual Abs were totally ineffective (42). A similar pattern
of C activation was obtained using combination of the anti-
EGFR Abs cetuximab and matuzumab, which recognize different
nonoverlapping epitopes of EGFR (79). Cetuximab was reported
to induce some degree of CDC in lung cancer cell lines only
at high concentrations (40µg/mL) (79), whereas lower amount
(10µg/mL) of either cetuximab or matuzumab failed to trigger C
activation. Interestingly, the mixture of the two Abs was able to
induce C1q and C4c fixation leading to strong activation of CDC
(50 and 80% of lysis of squamous cell carcinoma and glioblastoma
cells, respectively) (78).
Although this approach has not yet been introduced in
clinical practice, it represents a promising future development in
immunotherapy with C-fixing Abs.
Neutralization of membrane Complement Regulatory
Proteins
Different approaches based on anti-mCRP Abs or silencing
mCRP expression in combination with therapeutic Abs have
been evaluated in vitro and in vivo by various groups to
prevent the C-inhibitory effect of mCRP. We initially reported
an increased susceptibility of follicular and Burkitt’s lymphoma
cell lines to CDC induced by Rituximab in the presence
of Abs to CD55 and CD59 (46). These findings were later
confirmed using an in vivo model of human CD20+ B-
lymphoma established in severe combined immunodeficient
mice treated with rituximab in combination with anti-CD55
and anti-CD59 Abs that resulted in a significant animal survival
(56). Similar enhancing effect of anti-CD55 and anti-CD59
Abs was reported on C-mediated killing of two human lung
carcinoma cell lines induced by Herceptin (trastuzumab) (83).
Neutralizing Abs to CD46 and CD59 were instead required
to enhance CDC of ovarian carcinoma cells induced by the
mixture of cMOV18 and cMOV19 (42). Down-regulation of
all three mCRPs obtained with cationic liposomes (AtuPLEXes)
loaded with siRNAs proved effective in inducing substantial
increase of CDC of HER2 positive breast, lung and ovarian
adenocarcinoma cell lines stimulated by trastuzumab and
pertuzumab (84).
Although lysis of C-resistant tumor cells can be restored by
the addition of Abs neutralizing mCRPs, their use is limited
by the ubiquitous expression of mCRPs on both normal and
tumor cells. One way to avoid undesired side effects that may
derived from the binding of Abs to normal cells resulting in
decreased expression of mCRPs is to selectively deliver the Abs to
tumor cells. To this end, our group has generated two bispecific
Abs containing binding specificity to CD20 and either CD55 or
CD59. These Abs were able to recognize CD20 expressed on
Burkitt’s lymphoma cell lines and to neutralize membrane-bound
CD55 and CD59 enhancing cell susceptibility to C-mediated
lysis. An in vivomodel of Burkitt’s lymphoma developed in SCID
mice was used to investigate the tissue distribution of bispecific
Abs that were found to target selectively the tumor mass due
to the high affinity of the anti-CD20 portion as opposed to
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the lower affinity of the anti-CD55 or anti-CD59 arms and to
prevent tumor development (60). The therapeutic effect of the
Abs was largely dependent on C activation, as revealed by the
increased deposition of C3 and C9 in tumor masses, and also by
local recruitment of macrophages and NK cells. Importantly, the
combination of these two bispecific Abs resulted in the survival
of 100% of treatedmice whereas treatment with a single bispecific
recombinant Ab (MB20/55 or MB20/59) induced the survival of
only 20% of animals (60).
An interesting approach aimed at inhibiting mortalin, an heat
shock protein over-expressed in many cancer types, has been
proposed by Fishelson and his group (85) to interfere with MAC
formation and its release from cell surface. The level of mortalin
is inversely related to MAC deposition and its over-expression
in erythroleukemic cells protects from C activation through the
classical pathway, while protein down-regulation using specific
siRNA increases the level of cell-bound C9.
COMPLEMENT ACTIVATION
POTENTIATES STANDARD THERAPIES
Complement and Radiotherapy
Together with surgery and chemotherapy, radiotherapy is a
clinical mainstay of treatment for many malignancies especially
for aggressive tumors with poor prognosis.
Recent studies support an association between radiation
therapy for both human andmurine cancers and C activation. An
elegant study by Surace et al. (86) showed that local irradiation of
melanoma and colon carcinoma developing in mice with a single
dose of 20 or 5Gy resulted in rapid and transient C activation
triggered by tumor cells undergoing necrosis, apoptosis, and
mitotic catastrophe with the possible contribution of natural IgM
Abs bound to necrotic cells. In addition, they documented tumor
deposition of C3 activation products and local increases in C3a
and C5a, which induce maturation and activation of tumor-
associated dendritic cells expressing the receptors for these
anaphylatoxins and in turn promoting the anti-tumor activity
of CD8+ T lymphocytes. The important role of C activation
in the control of tumor growth was supported by the finding
that radiotherapy failed to exert a protective effect against the
tumor in mice deficient in either C3, or in C3a or C5a receptors,
suggesting the critical contribution of locally released C3a and
C5a.
Somewhat different results were obtained by Elvington et al.
(87) who used a lymphoma model in mice receiving low
dose radiotherapy fractionated over a period of approximately
5 months. They found that C inhibition induced by the
administration of CR2-Crry resulted in longer survival and
reduced tumor mass in tumor-bearing mice. A possible
explanation for these contrasting results is that a radiation
treatment administered over a prolonged period of time
induces a C-independent inflammatory response that contributes
to promote tumor growth. Overall, these data indicate that
dose and fractionation in the radiation therapy need to be
further investigated to find optimal conditions that combine
the beneficial anti-tumor effects of radiotherapy and C
activation.
Complement and Chemotherapy
Limited information is available on the interplay between the
C system and chemotherapeutic agents and the effect of this
interaction on tumor control.
Levels of C3 and C4 were measured in patients with breast
cancer treated with epirubicin/docetaxel-based neoadjuvant
chemotherapy and found to be substantially reduced (88).
This finding cannot be explained by C consumption because
the low concentrations of C3 and C4 were not associated
with a parallel increase in the level of the C activation
product C4d. The relevance of this observation is unclear
since the levels were equally reduced in responders and non-
responders to chemotherapy. A similar conclusion was reached
in another study that examined the changes in C activity in
patients with various types of cancer and revealed a significant
reduction in C activity which was not accompanied by a
corresponding increase in the level of C3d (89). More direct
evidence supporting the beneficial effect of a combination
therapy with a chemotherapeutic agent and a recombinant Ab
was obtained from a multicenter clinical trial conducted in
patients with advanced non-small-cell lung cancer (90). The
patients receiving the monoclonal Ab cetuximab directed against
epidermal growth factor receptor (EGFR) in combination with
cisplatin/vinorelbine survived longer than those treated with
the chemotherapeutic agents alone. In a subsequent study,
cetuximab was found to bind to a lung cancer cell line
expressing EGFR and to activate C resulting in the assembly of
FIGURE 1 | The ambivalent role of complement in tumor growth.
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the membrane attack complex and cell death. C involvement
in the killing of tumor cells was further documented by
the finding that the inhibitory effect of cetuximab on tumor
growth in an in vivo xenogeneic model of A549 lung cancer
cells in nude mice was abolished in tumor-bearing mice
treated with cobra venom factor to deplete C (79). These are
promising results that need to be confirmed using a similar
approach in the study of other tumors because the effect of
chemotherapy on C activation and the consequent impact of
these treatments on cancer cell killing may be different in various
tumors.
CONCLUSION
The introduction of recombinant Abs into the clinic to control
tumor growth has fostered the interest in C as an anti-
tumor defense system acting in close collaboration with other
components of both innate and acquired immunity. This has
prompted the development of various strategies to optimize
their therapeutic efficiency including structural modifications of
the Abs to promote C activation and also control C inhibitors
expressed on the tumor cell surface to enhance Ab-induced C-
mediated cell killing. Major efforts are being made to selectively
deliver mCRPs neutralizing agents to tumor cells and the recently
generated bispecific Abs that target cancer cells and inhibit mCRP
appear to move in this direction.
An important point to consider when adopting this
therapeutic approach is that C activated in the tumor
microenvironment, particularly in the case of slow growing
tumors associated with an inflammatory process developing in
the surrounding tissue, may promote cancer expansion due to
recruitment of suppressor cells by locally released C5a (Figure 1).
We believe that this undesired effect may be prevented or
markedly reduced by focusing Ab dependent C activation
on residual tumor cells after surgical removal or substantial
reduction of tumor mass after radio and/or chemotherapy. It
is important, though, that the protocols for radiation therapy
and chemotherapeutic treatment are selected to be highly
effective in the control of tumor growth with limited pro-
inflammatory side effects and negligible C activation in the tumor
microenvironment.
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